Biohacker Network
PeptidesEvidence: Early clinical

Ipamorelin: The Selective GH Secretagogue and Its Failed Phase-II Trial

Written by
Daniel Reyes, PhD
Medically reviewed by
Dr. Sarah Lindqvist, MD
Published
June 20, 2025
Updated
June 20, 2025
Last medical review
June 20, 2025
Reviewer scope
Metabolic health
Researcher pipetting samples into test tubes, reflecting ipamorelin’s early-clinical evidence base and discontinued development

Ipamorelin is a five-amino-acid ghrelin-receptor agonist notable for triggering GH release with minimal effect on cortisol and prolactin at studied doses — the selectivity behind its reputation. Its largest human program, a phase-II trial for postoperative ileus, missed its endpoints and development stopped. It is not FDA-approved, and long-term use has never been studied.

The selectivity finding, from 1998

The original characterization showed GH release comparable to GHRP-6 but without meaningful ACTH/cortisol or prolactin elevation at equivalent doses — genuinely unusual among secretagogues and the basis of every "cleanest GHRP" claim since.

Clinical trial samples in laboratory test tubes — ipamorelin’s phase-II program for postoperative ileus missed its endpoints and development stopped

The trial that gets left out of marketing

A randomized phase-II study testing ipamorelin for postoperative ileus after bowel resection did not meet its efficacy endpoints. A failed trial in one indication does not disprove others — but it is the largest controlled human dataset that exists, and it ended the compound’s development.

Its usual partner is covered in the CJC-1295 DAC guide and the combination in the stack evidence review. If timing conventions interest you, best time to take peptides explains the one rule with actual physiology behind it. Full compound profile: the ipamorelin monograph.

Open questions any user is volunteering to test

  • Long-term GH-axis effects at repeated "wellness" doses
  • Glucose and insulin-sensitivity impact over months
  • Appetite effects from ghrelin agonism
  • Purity of unregulated supply

Frequently asked questions

What makes ipamorelin "cleaner" than other GH peptides?
Its 1998 characterization showed GH release comparable to GHRP-6 but with minimal ACTH/cortisol and prolactin elevation at studied doses — genuine selectivity that is the basis of every "cleanest GHRP" claim since.
Did ipamorelin pass human trials?
No. Its largest human program — a randomized phase-II trial for postoperative ileus — missed its efficacy endpoints, and development stopped. That failed trial remains the biggest controlled human dataset on the compound.
Is ipamorelin FDA-approved or legal?
It is not FDA-approved for any use. It circulates as a gray-market research chemical, long-term use has never been studied, and GH secretagogues are prohibited for tested athletes.

Questions to ask a licensed clinician

  • What does the failed phase-II program imply for my expectations?
  • What baseline labs would matter before any GH-axis intervention?

References

  1. Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. SourcePharmacology
  2. Beck DE, Sweeney WB, McCarter MD, et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Neurogastroenterology & Motility. SourcePhase-II RCT
  3. US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice

Related tools

Related guides

Something incorrect in this guide? Report a correction. Material corrections are noted on the page with the date and nature of the change.